Filter By Category
Archives
Share on -
CADALIMOGENE IXALENTIVEC
Generic Name: CADALIMOGENE IXALENTIVEC
ABSTRACT -
Cadalimogene ixalentivec (CB-010) is an allogeneic, off-the-shelf CRISPR-engineered CAR-NK or CAR-T cell therapy under investigation for B-cell haematological malignancies. CRISPR editing removes immune rejection signals, enabling use of donor-derived cells without patient-matched manufacturing. Phase I evaluation is ongoing to determine safety and anti-tumour activity.
DOSAGE -
Single or multiple intravenous infusions following lymphodepleting conditioning; cell dose in allogeneic products expressed per fixed dose units per clinical protocol.
SIDE EFFECTS -
- Cytokine release syndrome
- Cytopenias
- Infections (immunocompromised state)
- Fatigue
- Fever
ALLERGIC REACTIONS -
-
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Infusion hypersensitivity
- Graft-versus-host disease (GvHD) risk in allogeneic products
- Anaphylaxis
- Urticaria
DRUG INTERACTIONS-
- Lymphodepleting chemotherapy co-administered — interactions with nephrotoxins relevant
- Avoid live vaccines post-infusion
- Corticosteroids for CRS management
PREAUTONS–
- Administered in specialised cellular therapy centre only
- Infectious disease screening mandatory
- Monitor for GvHD despite CRISPR editing
- Long-term follow-up for secondary malignancy
WARNINGS –
- Life-threatening CRS can occur
- GvHD risk even with engineered cells
- Product is allogeneic — off-the-shelf but requires specialised handling
Share on -
. Developed by